Blueprint executive chairman Jeff Albers and Blueprint CEO Kate Haviland (Brad Bahner Photography)

Blue­print Med­i­cines slips as it changes end­point for tri­al in aim to great­ly broad­en Ay­vak­it la­bel

Blue­print is forg­ing ahead on its slow crawl to broad­en its mar­ket for Ay­vak­it.

Hav­ing nabbed its fourth ap­proval for the drug in 2021 for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.